Früherkennung und
Früherkennung und Diagnose von Herz-Kreislauf-Erkrankungen:Ein Manifest für VeränderungLiteraturverzeichnis1. American Heart Association. nd. Atherosclerotic Cardiovascular Disease (ASCVD). Available from: https://www.heart.org/en/professional/quality-improvement/ascvd [Accessed 29/02/2024]2. British Heart Foundation. nd. Familial hypercholesterolaemia. Available from: https://www.bhf.org.uk/informationsupport/conditions/familial-hypercholesterolaemia [Accessed 18/12/2023]3. National Health System (NHS). nd. Overview: heart failure Available from: https://www.nhs.uk/conditions/heart-failure/[Accessed 06/12/2023]4. World Health Organization. 2021. Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-(cvds)[Accessed 27/11/2023]5. Thiriet M. 2018. Cardiovascular Disease: An Introduction. Vasculopathies: Behavioral, Chemical, Environmental, and GeneticFactors. Berlin: Springer: 1-906. Roth G, Mensah G, Johnson C, et al. 2020. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: UpdateFrom the GBD 2019 Study. Journal of the American College of Cardiology 76(25): 2982-30217. United Nations Department of Economic and Social Affairs. 2012. Population ageing and the non-communicable diseases.New York: United Nations8. World Health Organization, United Nations Development Programme. 2016. What ministries of labour and employment needto know. Gevena: World Health Organization and United Nations Development Programme9. European Society of Cardiology. 2023. Price tag on cardiovascular disease in Europe higher than entire EU budget. Availablefrom: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Price-tag-on-cardiovascular-disease-in-Europehigher-than-entire-EU-budget[Accessed 13/02/2024]10. Schweikert B, Hunger M, Meisinger C, et al. 2008. Quality of life several years after myocardial infarction: comparing theMONICA/KORA registry to the general population†. European Heart Journal 30(4): 436-4311. Rad M, Ghanbari-Afra l, Hoseini M, et al. 2021. Effectiveness of self-care program on the quality of life in patients withcoronary artery disease undergoing cardiac rehabilitation: A Randomized clinical trial. Journal of Education and HealthPromotion 10: 10.4103/jehp.jehp_70_2112. World Heart Federation. 2022. World Heart Vision 2030: Driving policy change. Geneva: World Heart Federation13. LSE Consulting. 2023. Trends in avoidable mortality from cardiovascular disease in the European Union. London: LSEConsulting14. Quinn G, Ranum D, Song E, et al. 2017. Missed Diagnosis of Cardiovascular Disease in Outpatient General Medicine: Insightsfrom Malpractice Claims Data. The Joint Commission Journal on Quality and Patient Safety 43(10): 508-1615. Fleming K, Horton S, Wilson M, et al. 2021. The Lancet Commission on diagnostics: transforming access to diagnostics. Lancet398: 1997-205016. Public Health England. 2019. Health matters: preventing cardiovascular disease. Available from: https://www.gov.uk/government/publications/health-matters-preventing-cardiovascular-disease/health-matters-preventing-cardiovasculardisease[Accessed 28/11/2023]17. Bottle A, Kim D, Aylin P, et al. 2018. Routes to diagnosis of heart failure: observational study using linked data in England. Heart104(7): 600-0518. d’Arcy J, Coffey S, Loudon M, et al. 2016. Large-scale community echocardiographic screening reveals a major burden ofundiagnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. European Heart Journal 37(47):3515-2219. Groenewegen A, Zwartkruis V, Rienstra M, et al. 2021. Improving early diagnosis of cardiovascular disease in patientswith type 2 diabetes and COPD: protocol of the RED-CVD cluster randomised diagnostic trial. BMJ Open 11(10): 10.1136/bmjopen-2020-04633020. Freedman B, Hindricks G, Banerjee A, et al. 2021. World Heart Federation roadmap on atrial fibrillation - A 2020 update.Global Heart 16(1): 10.5334/gh.1023.21. Ray K, Ference B, Séverin T, et al. 2022. World Heart Federation cholesterol roadmap 2022. Global Heart 17(1): 10.5334/gh.115422. Global Heart Hub. 2022. Cardio-diabetes think tank: Call to action. Galway: Global Heart Hub23. Ferreira J, Kraus S, Mitchell S, et al. 2019. World Heart Federation roadmap for heart failure. Global Heart 14(3): 197-21426
GLOBAL HEART HUB24. Iyer P, Moreno G, Caneo L, et al. 2017. Management of late presentation congenital heart disease. Cardiology in the Young27(S6): S31-S3925. Banderali G, Capra M, Biasucci G, et al. 2022. Detecting Familial hypercholesterolemia in children and adolescents: potentialand challenges. Italian Journal of Pediatrics 48: 10.1186/s13052-022-01257-y26. Bedlington N, Abifadel M, Beger B, et al. 2022. The time is now: achieving FH paediatric screening across Europe - ThePrague Declaration. GMS Health Innovation and Technologies 16: 10.3205/hta00013627. MedTech Europe. 2021. An EU action plan for better cardiovascular health. Brussels: MedTech Europe28. Hill N, Sandler B, Mokgokong R, et al. 2020. Cost-effectiveness of targeted screening for the identification of patients withatrial fibrillation: evaluation of a machine learning risk prediction algorithm. Journal of Medical Economics 23(4): 386-9329. Bobrowska A, Seedat F. 2022. Updated definition of targeted screening will help clarify remit of expanded UK NSC. Availablefrom: https://nationalscreening.blog.gov.uk/2022/05/26/updated-definition-of-targeted-screening-will-help-clarify-remitof-expanded-uk-nsc/[Accessed 27/11/2023]30. Marquina C, Morton J, Lloyd M, et al. 2024. Cost-effectiveness of screening strategies for familial hypercholesterolaemia: anupdated systematic review. PharmacoEconomics: 10.1007/s40273-023-01347-731. European Alliance for Cardiovascular Health. 2022. A European cardiovascular health plan: The need and the ambition.Brussels: European Alliance for Cardiovascular Health32. O’Kelly A, Michos E, Shufelt C, et al. 2022. Pregnancy and Reproductive Risk Factors for Cardiovascular Disease in Women.Circulation Research 130(4): 652-7233. Wait S, Krishnaswamy P, Borregaard B, et al. 2020. Heart valve disease: working together to create a better patient journey.London: The Health Policy Partnership and the Global Heart Hub34. Unite Annual Summit participant (anon). 2023. Statement made during expert workshop. Global Heart Hub Unite AnnualSummit October, 2023; Barcelona35. Pastore F, Parisi V, Romano R, et al. 2013. Genetic test for dilated and hypertrophic cardiomyopathies: useful or less thanuseful for patients? Translational medicine @ UniSa, 5: 14-736. Liao M, Wu C, Juang J, et al. 2021. Atrial fibrillation and the risk of sudden cardiac arrest in patients with hypertrophiccardiomyopathy - A nationwide cohort study. eClinicalMedicine 34: 10.1016/j.eclinm.2021.10080237. Low Wang C, Hess C, Hiatt W, et al. 2016. Clinical update: cardiovascular disease in diabetes mellitus: atheroscleroticcardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations.Circulation 133(24): 2459-50238. Almdal T, Scharling H, Jensen J, et al. 2004. The independent effect of type 2 diabetes mellitus on ischemic heart disease,stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Archives of InternalMedicine 164(13): 1422-639. Gill J, Miracolo A, Politopoulou K, et al. 2024. How can we improve the secondary prevention of cardiovascular disease?London: London School of Economics40. McCracken C, Raisi-Estabragh Z, Szabo L, et al. 2024. NHS Health Check attendance is associated with reduced multiorgandisease risk: a matched cohort study in the UK Biobank. BMC Medicine 22(1): 10.1186/s12916-023-03187-w41. Morton J, Marquina C, Lloyd M, et al. 2023. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease inthe UK: A Cost-Effectiveness Analysis. PharmacoEconomics 42(1): 91-10742. ClinRisk. 2017. Welcome to the QRISK®3-2018 risk calculator Available from: https://www.qrisk.org/ [Accessed 13/02/2024]43. National Health System. 2021. Annex A - Primary Care Networks - Plans for 2021/22 and 2022/23 - New PCN servicerequirements. Leeds: National Health System44. Lingervelder D, Koffijberg H, Emery J, et al. 2022. How to Realize the Benefits of Point-of-Care Testing at the General Practice:A Comparison of Four High-Income Countries. International Journal of Health Policy and Management 11(10): 2248-6045. Hasin T, Zalut T, Hasin Y. 2018. Managing the Patient with Heart Failure in the Emergency Department. European HeartJournal 39(38): 3493-9546. British Heart Foundation. 2023. Numbers of heart patients waiting over four months at record high. Available from: https://www.bhf.org.uk/what-we-do/news-from-the-bhf/news-archive/2023/april/numbers-of-heart-patients-waiting-over-fourmonths-at-record-high[Accessed 06/12/2023]27
